Wilson Sonsini Goodrich & Rosati advised Noctrix Health on the transaction. Noctrix Health Inc. announced it has closed a $40 million Series C financing round led...
Noctrix Health’s $40 Million Series C Financing Round
Foresight Diagnostics’ $58.75 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresight on the deal. Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an...
Akili’s Licensing Agreement with TALi
Wilson Sonsini Goodrich & Rosati advised Akili on the deal. PureTech Health plc (PureTech), a clinical-stage biotherapeutics company, announced that its Founded Entity, Akili Interactive (Akili),...
Leo Cancer Care’s $25.3 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Leo Cancer Care on the deal. Leo Cancer Care, an innovative start-up that is set to change the face of...
Ceribell’s $53 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Ceribell on the deal. Ceribell, innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced the completion of...